Monoclonal antibody against delta-like ligand 3 and use thereof

By designing monoclonal antibodies against delta-like ligand 3 with specific CDR sequences and conjugating them with cytotoxic drugs, the problem of insufficient affinity and specificity of antibody-drug conjugates in existing technologies has been solved. This has achieved highly efficient targeting and killing effects on tumors with high expression of delta-like ligand 3, and has significant in vivo antitumor activity.

CN120504738BActive Publication Date: 2025-10-21NANJING DILI BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202511008778.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-07-21
Publication Date
2025-10-21
Estimated Expiration
2045-07-21

AI Technical Summary

Technical Problem

The lack of high-affinity and high-specificity anti-δ-like ligand 3 monoclonal antibodies in the current technology has led to insufficient development of antibody-drug conjugates targeting neuroendocrine tumors, affecting treatment efficacy and side effect control.

Method used

A monoclonal antibody against delta-like ligand 3 was designed and prepared, containing specific light chain and heavy chain variable region (CDR) sequences. It was then coupled with a cytotoxic drug via a linker to form an antibody-drug conjugate, thereby improving the targeting and killing efficacy against delta-like ligand 3.

Benefits of technology

It achieved high endocytosis efficiency and strong targeting of cells with high expression of δ-like ligand 3, significantly reduced tumor volume in tumor-bearing mice, and showed good in vivo antitumor activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN120504738B_ABST
    Figure CN120504738B_ABST
Patent Text Reader

Abstract

The present application relates to a kind of anti-delta-like ligand 3 monoclonal antibody and its application, belong to biotechnology field.The present application provides a kind of anti-delta-like ligand 3 (DLL3) monoclonal antibody, research shows that this monoclonal antibody has high affinity and high specificity to delta-like ligand 3, and, this monoclonal antibody has high endocytosis efficiency in the cell of delta-like ligand 3 high expression;Meanwhile, research shows that the antibody conjugated drug obtained by linker coupling of this monoclonal antibody and antitumor drug has strong target cell killing activity, and the antibody conjugated drug obtained by linker coupling of this monoclonal antibody and antitumor drug has better in vivo anti-tumor activity, it can be seen that this monoclonal antibody can effectively target neuroendocrine tumor, in the preparation of neuroendocrine tumor treatment drug, it is extremely applied prospect.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-DLL3 antibody, and preparation method, drug conjugate and application thereof

    CN116271079A

  • Canine antibodies with modified CH2-CH3 sequences

    CN113402609A

  • Anti-CEA antibody-exatecan analog conjugate and pharmaceutical use thereof

    US20230055408A1